真穴与假穴穴位埋线治疗肥胖的疗效:随机对照试验研究方案
该随机对照试验计划招募99例肥胖患者,随机分为真穴埋线组、假穴埋线组和等待名单组,每组33例;两个埋线组各接受8次治疗、持续8周,主要结局为治疗后体重指数下降。研究旨在评估穴位埋线对肥胖相关临床变量及内脏脂肪面积的影响,为穴位埋线治疗肥胖的疗效提供高质量证据。
要点
- 真穴埋线组、假穴埋线组和等待名单组各33例,共99例肥胖患者。
- 两个埋线组各接受8次治疗、持续8周,主要结局为治疗后体重指数下降。
- 结局在基线、8周治疗结束时和3个月随访时评估,评估者和数据分析者设盲。
核心结论
- 这项随机、假穴和等待名单对照试验的结果将有助于探究穴位埋线对肥胖临床变量及内脏脂肪面积的影响,为穴位埋线治疗肥胖的疗效提供高质量证据。
研究设计与样本
- 随机对照试验,计划招募99例诊断为肥胖的合格患者,随机分配至真穴埋线组、假穴埋线组或等待名单组,每组33例。
- 两个埋线组各接受8次治疗,持续8周。
- 评估者和数据分析者将对分组设盲。
- 试验注册于中国临床试验注册中心,注册号ChiCTR1800020248,注册日期2018年12月21日。
主要发现
- 主要结局为治疗后体重指数下降。
- 次要结局包括腰围、臀围、腰臀比、体脂百分比、血脂水平、皮下脂肪面积、内脏脂肪面积和世界卫生组织生活质量量表(WHOQOL)。
- 所有结局在基线、8周治疗结束时和3个月随访时评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity has become a major public health hazard with epidemic proportions, affecting adults, adolescents, and children of both genders. Previous studies have suggested that acupoint catgut embedding (ACE) might be a potential therapeutic approach for obesity. The purpose of this study is to conduct a rigorous and normative trial to determine the efficacy of ACE for obesity. METHODS/DESIGN: A total of 99 eligible patients diagnosed with obesity will be recruited in this study. They will be randomly allocated to either the verum ACE group, sham ACE group, or waiting list (WL) group, with 33 patients in each group. Each patient in the two ACE-based groups will receive eight sessions of treatment, lasting over 8 weeks. The primary outcome is the reduction of body mass index (BMI) after treatment. Secondary outcomes will include waist circumference (WC), hip circumference (HC), waist:hip ratio, body fat percentage, blood lipid level, subcutaneous fat area, visceral fat area, and World Health Organization Quality of Life (WHOQOL). All the outcomes will be evaluated at baseline, at the end of the 8 weeks of treatments, and at 3 months of follow-up. The evaluators and data analyzers will be blinded to group allocation. DISCUSSION: The findings of this randomized, sham-, and WL-controlled trial will help to investigate the influence of ACE on clinical variables as well as visceral fat area of obesity, which will provide high-quality evidence on the efficacy of ACE for obesity. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800020248. Registered on December 21, 2018.
引用
- Zhou YM, Yan B, Yuan WQ, et al. Efficacy of verum and sham acupoint catgut embedding for treatment of obesity: Study protocol for a randomized controlled trial. Trials. 2019. PMID: 31775839. doi:10.1186/s13063-019-3730-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。